Terms: = Breast cancer AND CSF3R, CD114, 1441, ENSG00000119535, GCSFR AND Treatment
15 results:
1. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative breast cancer.
Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
[TBL] [Abstract] [Full Text] [Related]
2. Detection of internal mammary chain infiltration in breast cancer patients by [
Garcia JR; Kauak M; Compte A; Bassa P; Llinares E; Valls E; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(2):73-78. PubMed ID: 37865228
[TBL] [Abstract] [Full Text] [Related]
3. breast cancer trends in women younger than 40 years in Brazil.
Bonadio RC; Moreira OA; Testa L
Cancer Epidemiol; 2022 Jun; 78():102139. PubMed ID: 35290906
[TBL] [Abstract] [Full Text] [Related]
4. [Ramadan fasting during treatment with external beam radiotherapy].
Lachgar A; Ridai S; Mouafik S; Kaiss H; Sahli N; Jouhadi H; Benider A
Bull Cancer; 2022 Mar; 109(3):331-337. PubMed ID: 34776116
[TBL] [Abstract] [Full Text] [Related]
5. HiFreSP: A novel high-frequency sub-pathway mining approach to identify robust prognostic gene signatures.
Li M; Zhao J; Li X; Chen Y; Feng C; Qian F; Liu Y; Zhang J; He J; Ai B; Ning Z; Liu W; Bai X; Han X; Wu Z; Xu X; Tang Z; Pan Q; Xu L; Li C; Wang Q; Li E
Brief Bioinform; 2020 Jul; 21(4):1411-1424. PubMed ID: 31350847
[TBL] [Abstract] [Full Text] [Related]
6. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK
Breast Cancer Res Treat; 2019 Feb; 174(1):271-278. PubMed ID: 30465154
[TBL] [Abstract] [Full Text] [Related]
7. Mechanisms of Acquired Resistance to Trastuzumab Emtansine in breast cancer Cells.
Li G; Guo J; Shen BQ; Yadav DB; Sliwkowski MX; Crocker LM; Lacap JA; Phillips GDL
Mol Cancer Ther; 2018 Jul; 17(7):1441-1453. PubMed ID: 29695635
[TBL] [Abstract] [Full Text] [Related]
8. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.
Yorulmaz A; Dogan M; Artuz F; Zengin N
Cutan Ocul Toxicol; 2017 Jun; 36(2):135-139. PubMed ID: 27086693
[TBL] [Abstract] [Full Text] [Related]
10. Validation of self-reported post-treatment mammography surveillance among breast cancer survivors by electronic medical record extraction method.
Tiro JA; Sanders JM; Shay LA; Murphy CC; A Hamann H; Bartholomew LK; Savas LS; Vernon SW
Breast Cancer Res Treat; 2015 Jun; 151(2):427-34. PubMed ID: 25922083
[TBL] [Abstract] [Full Text] [Related]
11. Nestin: predicting specific survival factors for breast cancer.
Gao N; Xu H; Liu C; Xu H; Chen G; Wang X; Li Y; Wang Y
Tumour Biol; 2014 Mar; 35(3):1751-5. PubMed ID: 24443256
[TBL] [Abstract] [Full Text] [Related]
12. Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors.
Axelson H; Fredlund E; Ovenberger M; Landberg G; Påhlman S
Semin Cell Dev Biol; 2005; 16(4-5):554-63. PubMed ID: 16144692
[TBL] [Abstract] [Full Text] [Related]
13. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials.
Sze WM; Shelley M; Held I; Mason M
Cochrane Database Syst Rev; 2004; 2002(2):CD004721. PubMed ID: 15106258
[TBL] [Abstract] [Full Text] [Related]
14. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract] [Full Text] [Related]
15. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.
Jaeckle KA; Phuphanich S; Bent MJ; Aiken R; Batchelor T; Campbell T; Fulton D; Gilbert M; Heros D; Rogers L; O'Day SJ; Akerley W; Allen J; Baidas S; Gertler SZ; Greenberg HS; LaFollette S; Lesser G; Mason W; Recht L; Wong E; Chamberlain MC; Cohn A; Glantz MJ; Gutheil JC; Maria B; Moots P; New P; Russell C; Shapiro W; Swinnen L; Howell SB
Br J Cancer; 2001 Jan; 84(2):157-63. PubMed ID: 11161370
[TBL] [Abstract] [Full Text] [Related]
